{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:04:18Z","timestamp":1770743058903,"version":"3.49.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study analyzes trends in Medicare Part D use and spending on oral-targeted drugs for chronic lymphocytic leukemia from 2014 to 2020.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2023.7467","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:01:31Z","timestamp":1680879691000},"page":"e237467","source":"Crossref","is-referenced-by-count":3,"title":["Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020"],"prefix":"10.1001","volume":"6","author":[{"given":"Edward R. Scheffer","family":"Cliff","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"issue":"4","key":"zld230047r1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat\u2019s past is prologue\u201d (Shakespeare).","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zld230047r3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2019.241539","article-title":"Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.","volume":"106","author":"Eyre","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"zld230047r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002872","article-title":"Competition and price among brand-name drugs in the same class: a systematic review of the evidence.","volume":"16","author":"Sarpatwari","year":"2019","journal-title":"PLoS Med"},{"issue":"5","key":"zld230047r6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1377\/hlthaff.2017.1684","article-title":"Generic price competition for specialty drugs: too little, too late?","volume":"37","author":"Cole","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"zld230047r2","unstructured":"Mikulic? M. Leading cancer drugs worldwide by revenue in 2020. Accessed October 24, 2022. https:\/\/www.statista.com\/statistics\/288538\/top-cancer-drugs-based-on-revenue\/"},{"key":"zld230047r4","unstructured":"Centers for Medicare & Medicaid Services. Medicare part D prescribers by geography and drug dataset February 2022. Accessed October 1, 2022. https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-part-d-prescribers\/medicare-part-d-prescribers-by-geography-and-drug"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803484\/cliff_2023_ld_230047_1680183111.00937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:01:34Z","timestamp":1680879694000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7467","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}